

SHB 1668 - H COMM AMD

By Committee on Appropriations

1 On page 2, beginning on line 2, after "regulate all" strike
2 "cannabinoids that may be impairing" and insert "impairing
3 cannabinoids"

4 On page 3, beginning on line 19, after "product of" strike "a
5 cannabinoid that may be impairing" and insert "an impairing
6 cannabinoid"

7 On page 5, line 29, after "(aa)" insert "Impairing cannabinoid"
8 means a substance that meets each of the following structural and
9 functional criteria:

10 (1) Exhibits the structural backbone of tetrahydrocannabinols and
11 tetrahydrocannabinol-like molecules that include the interconnected
12 three-ring system of either a six-carbon aromatic ring, a pyran ring,
13 or a cyclohexene ring. Known compounds that fit this description
14 include:

15 (i) Tetrahydrocannabinols. A single double-bond in the C ring,
16 such as delta-10 tetrahydrocannabinol and isomers, delta-9
17 tetrahydrocannabinol and isomers, delta-8-tetrahydrocannabinol and
18 isomers, delta-7-tetrahydrocannabinol and isomers, delta-6a
19 tetrahydrocannabinol and isomers, and delta-10a tetrahydrocannabinol
20 and isomers;

21 (ii) Carboxylates (C-2 and C-4) of tetrahydrocannabinols, such as
22 delta-9-tetrahydrocannabinolic acid, similar carboxylates of delta-9-
23 tetrahydrocannabinolic acid for tetrahydrocannabinols such as in
24 (1)(i) of this subsection, and carboxylate esters of
25 tetrahydrocannabinols in (1)(i) of this subsection;

26 (iii) Alkyl analogues (C-3) of tetrahydrocannabinols, such as
27 delta-9-tetrahydrocannabiphorol and n-alkyl analogues, and similar
28 alkylated analogues of delta-9-tetrahydrocannabinol for
29 tetrahydrocannabinols in (1)(i) of this subsection; and

30 (iv) Hydroxylated analogues of tetrahydrocannabinols, such as 11-
31 hydroxy-delta-9-tetrahydrocannabinol and 8- and 10-hydroxy analogues,

1 and similar hydroxylated analogues of delta-9 tetrahydrocannabinol
2 for tetrahydrocannabinols in (1)(i) of this subsection;

3 (2) Possesses significant CB1 agonist activity as demonstrated by
4 binding affinity (K_i) to the CB1 receptors at less than 200 nM; and

5 (3) Results in positive effects for all four components of the
6 tetrad test in rodents or reliably causes functional impairment in
7 humans as assayed by a method possessing scientific consensus.

8 (bb)"

9 Reletter the remaining subsections consecutively and correct any
10 internal references accordingly.

11 On page 7, beginning on line 27, after "package of" strike "a
12 cannabinoid that may be impairing" and insert "an impairing
13 cannabinoid"

14 On page 11, beginning on line 27, after "product of" strike "a
15 cannabinoid that may be impairing" and insert "an impairing
16 cannabinoid"

17 On page 11, beginning on line 32, after "marketed as" strike
18 "having impairing effects" and insert "being impairing cannabinoids"

19 On page 12, line 6, after "Products containing" strike
20 "cannabinoids that may be impairing" and insert "impairing
21 cannabinoids"

22 On page 12, at the beginning of line 11, strike "cannabinoid that
23 may be impairing" and insert "impairing cannabinoid"

24 On page 13, beginning on line 15, after "serving of" strike "a
25 cannabinoid that may be impairing" and insert "an impairing
26 cannabinoid"

27 On page 13, line 37, after "serving of" strike "a cannabinoid
28 that may be impairing" and insert "an impairing cannabinoid"

29 On page 15, at the beginning of line 38, strike "cannabinoid that
30 may be impairing" and insert "impairing cannabinoid"

31 On page 16, line 11, after "substance that" strike "may be
32 impairing" and insert "is an impairing cannabinoid"

1 On page 20, at the beginning of line 1, strike "cannabinoids that
2 may be impairing" and insert "impairing cannabinoids"

3 On page 25, after line 19, insert the following:

4 "NEW SECTION. Sec. 12. A new section is added to chapter 69.50
5 RCW to read as follows:

6 (1) The Washington State University center for cannabis policy,
7 research, and outreach shall convene a scientific panel, with members
8 as provided in subsection (2) of this section, to review available
9 scientific research, data, and regulations of other jurisdictions
10 related to cannabinoids and the regulation of cannabinoids including,
11 but not limed to:

12 (a) Definitions of impairing cannabinoids;

13 (b) Definitions of synthetic cannabinoids, synthetically derived
14 cannabinoids, and artificial cannabinoids; and

15 (c) Health and safety considerations related to the conversion
16 process and consumption of cannabinoids.

17 (2) The scientific panel shall consist of the following members:

18 (a) One representative from Washington State University,
19 designated by the dean of Washington State University;

20 (b) One representative from the University of Washington,
21 designated by the dean of the University of Washington;

22 (c) One representative who holds a cannabis research license
23 issued by the board;

24 (d) One representative from a certified cannabis testing
25 laboratory; and

26 (e) One person who is a regulatory expert experienced with
27 regulations of the United States food and drug administration on
28 consumable products.

29 (3) The scientific panel convened under this section shall
30 compile findings and make recommendations to the legislature
31 regarding regulating cannabinoids in the adult-use cannabis market,
32 with a report submitted to the legislature by December 1, 2022, and
33 annual updates to the legislature thereafter."

34 Renumber the remaining section consecutively, correct any
35 internal references accordingly, and correct the title.

EFFECT: (1) Adds a definition of the term "impairing cannabinoid"
to the Uniform Controlled Substances Act. Defines the term as a

substance that meets all the following structural and functional criteria:

(a) The substance exhibits the structural backbone of tetrahydrocannabinols and tetrahydrocannabinol-like molecules that include the interconnected three-ring system of either a six-carbon aromatic ring, a pyran ring, or a cyclohexene ring (specific known compounds that fit this structural backbone criterion are identified in the definition);

(b) The substance possesses significant CB1 agonist activity as demonstrated by binding affinity (K_i) to the CB1 receptors at less than 200 nM; and

(c) The substance results in positive effects for all four components of the tetrad test in rodents or reliably causes functional impairment in humans as assayed by a method possessing scientific consensus.

(2) Uses the new term "impairing cannabinoid" to replace the phrase "cannabinoid that may be impairing" and similar references in the bill.

(3) Requires the Washington State University Center for Cannabis Policy, Research, and Outreach to convene a five-member scientific panel to review available scientific research, data, and regulations of other jurisdictions related to cannabinoids and the regulation of cannabinoids including, but not limited to: (a) Definitions of impairing cannabinoids; (b) definitions of synthetic cannabinoids, synthetically derived cannabinoids, and artificial cannabinoids; and (c) health and safety considerations related to the conversion process and consumption of cannabinoids. Requires a report to the Legislature by December 1, 2022, with annual updates thereafter.

--- END ---